Last €9.55 EUR
Change Today -0.025 / -0.26%
Volume 0.0
VM4 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 2:08 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VM4) Snapshot

Open
€9.51
Previous Close
€9.57
Day High
€9.55
Day Low
€9.51
52 Week High
03/19/14 - €13.51
52 Week Low
11/8/13 - €4.30
Market Cap
323.4M
Average Volume 10 Days
200.0
EPS TTM
--
Shares Outstanding
33.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VANDA PHARMACEUTICALS INC (VM4)

vanda pharmaceuticals inc (VM4) Related Businessweek News

No Related Businessweek News Found

vanda pharmaceuticals inc (VM4) Details

Vanda Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development and commercialization of pharmaceutical products. Its product portfolio includes HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder; Fanapt, a product for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

56 Employees
Last Reported Date: 08/8/14
Founded in 2002

vanda pharmaceuticals inc (VM4) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $515.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $279.8K
Compensation as of Fiscal Year 2013.

vanda pharmaceuticals inc (VM4) Key Developments

Vanda Pharmaceuticals, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

Vanda Pharmaceuticals, Inc. reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $10,862,000 against $8,319,000 a year ago. Loss from operations was $21,606,000 against $3,413,000 a year ago. Loss before tax benefit was $21,575,000 against $3,383,000 a year ago. Net loss was $21,575,000 or $0.64 per basic and diluted share against $3,383,000 or $0.12 per basic and diluted share a year ago. For the six months, the company reported total revenues of $20,005,000 against $16,387,000 a year ago. Loss from operations was $48,184,000 against $7,978,000 a year ago. Loss before tax benefit was $48,108,000 against $7,902,000 a year ago. Net loss was $48,108,000 or $1.42 per basic and diluted share diluted against $7,902,000 or $0.28 per basic and diluted share a year ago. Net cash used in operating activities was $60,569,000 against $17,168,000 a year ago.

Vanda Pharmaceuticals, Inc. to Report Q2, 2014 Results on Aug 07, 2014

Vanda Pharmaceuticals, Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Aug 07, 2014

Vanda Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 07, 2014

Vanda Pharmaceuticals, Inc., Q2 2014 Earnings Call, Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VM4:GR €9.55 EUR -0.025

VM4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,579 GBp +42.00
Eli Lilly & Co $66.53 USD -0.06
Sanofi €88.76 EUR +0.30
Sumitomo Dainippon Pharma Co Ltd ¥1,408 JPY +19.00
Transcept Pharmaceuticals Inc $2.11 USD -0.02
View Industry Companies
 

Industry Analysis

VM4

Industry Average

Valuation VM4 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.8x
Price/Book 459.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit www.vandapharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.